Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07249489

Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada

The goal of this First in Human study is to learn if the Nanochon Chondrograft Implant is a safe primary surgical treatment for participants with cartilage lesions in the knee. This study will include males and females between the ages of 22 and 60.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of British Columbia, Vancouver, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female ≥22 years and ≤ 60 years of age
  • MRI knee evaluation completed within 6 months prior to enrollment
  • Participant must be able to read and speak English
  • Participant must voluntarily sign the REB approved informed consent form (ICF)

Exclusion criteria

  • Any known systemic cartilage and/or bone disorder, such as, but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta
  • Requires bilateral knee surgery
  • Pregnancy, planning to become pregnant or breast feeding
  • Any significant illness (metastasis cancer of any type) that decreases the probability of the participant's survival to 12 months
  • Known insulin dependent diabetes mellitus
  • Steroid treatment (oral or IV) within the past 6 months
  • Participant is:
  • receiving workman's compensation
  • receiving prescription narcotic medication
  • active with litigation relating to musculoskeletal injuries or disorders
  • a prisoner or pending incarceration
  • Comorbidities that could impact study participation or results (e.g., autoimmune disorder, HIV, neuropathic pain or fibromyalgia, restless leg syndrome, active infection, or pain requiring chronic pain management), in the opinion of the investigator at the time of enrollment
  • Significant psychiatric disorders (e.g., major depression, anxiety disorders, bipolar disorder, and schizophrenia)
  • Substance and/or alcohol dependence and/or abuse based on clinical history, physical exam and participant presentation
  • Current participation in another drug or device study that, in the opinion of the investigator at the time of enrollment, would interfere with participation in this study
  • Participant has claustrophobia or implanted metallic devices (e.g., cardiac pacemakers, insulin pumps, nerve stimulators), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI
  • Known allergy or hypersensitivity to any investigational device materials.

Treatment and study plan

Nanochon Chondrograft

Device

Mini arthrotomy or arthroscopic surgical implantation of the Nanochon Chondrograft

Primary outcomes

  1. Serious Adverse Device Event Effects

    Time frame: Month 12

    Absence of Serious Adverse Device Event Effects (SADEs) through Month 12

Study contacts

Contact information is provided by the study sponsor or research team.

Chief Clinical Officer

CONTACT

[email protected]

615-483-7438

Sponsors and collaborators

Lead sponsor

Nanochon, Inc.

Industry

Registry information

Official study title

A First in Human (FIH) Early Feasibility Study (EFS) to Evaluate the Safety and Performance of the Nanochon Chondrograft™ Implant for Re-surfacing of Cartilage Lesions

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 25, 2025
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.